We typically use high CIN (Rad21 depletion) where we are measuring strong CIN phenotypes and low CIN (Mad2 depletion) where we are testing for genetic enhancement of mild CIN effects. This evidence concerns the gene RAD21 and cervical squamous intraepithelial neoplasia.